Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

By Palmer Andrew   Valentine William   Ray Joshua   Roze Stephane   Muszbek Noemi  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 161-168

Springer Publishing Company

Access to resources Recommend Favorite

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

By Persson Frederik   Rossing Peter   Hovind Peter   Stehouwer Coen   Schalkwijk Casper   Tarnow Lise   Parving Hans-Henrik  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 68, Iss. 8, 2008-01 ,pp. : 731-738

Informa Healthcare

Access to resources Recommend Favorite

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

By Palmer Andrew J.   Dinneen Sean   Gavin James R.   Gray Alastair   Herman William H.   Karter Andrew J.  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 861-872

Informa Healthcare

Access to resources Recommend Favorite

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

By Bullano Michael F.   Al-Zakwani Ibrahim S.   Fisher Maxine D.   Menditto Laura   Willey Vincent J.  

Current Medical Research and Opinion, Vol. 21, Iss. 2, 2005-02 ,pp. : 291-298

Informa Healthcare

Access to resources Recommend Favorite

Serum Levels of the Advanced Glycation End Products N^ε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

By  

Nephron Clin Pract, Vol. 108, Iss. 4, 2008-04 ,pp. : c291-c297

Karger

Access to resources Recommend Favorite